L-Cycloserine
- Generic Name
- L-Cycloserine
- Brand Names
- Seromycin
- Drug Type
- Small Molecule
- Chemical Formula
- C3H6N2O2
- CAS Number
- 339-72-0
- Unique Ingredient Identifier
- AK7DRB7FMO
- Background
Antibiotic substance produced by Streptomyces garyphalus.
- Indication
本品与其他抗结核药联合，用于经一线药物（如吡嗪酰胺、链霉素、异烟肼、利福平和乙胺丁醇）治疗失败的患者。本品还可用于治疗非结核分枝杆菌感染如鸟复合分枝杆菌病的治疗。
- Associated Conditions
- Pulmonary Tuberculosis (TB), Tuberculosis, Extrapulmonary, Grade 1, grade 2, grade 3, grade 4 Urinary Tract Infection
- Associated Therapies
- -
RCT of CBT Combined With D-Cycloserine for Treating PTSD
- Conditions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2007-03-27
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 20
- Registration Number
- NCT00452231
- Locations
- 🇨🇦
Centre d'étude sur le Trauma, Montréal, Quebec, Canada
Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Boston University Charles River Campus
- Target Recruit Count
- 15
- Registration Number
- NCT00430573
- Locations
- 🇺🇸
Habit OPCO, Boston, Massachusetts, United States
D-cycloserine for Major Depressive Disorder
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- Herzog Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT00408031
- Locations
- 🇮🇱
Ezrath Nashim - Herzog Memorial Hospital & Community Clinics, Jerusalem, Israel
🇮🇱Ezrath Nashim - Herzog Memorial Hospital, Jerusalem, Israel
A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD
- Conditions
- Interventions
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 26
- Registration Number
- NCT00371176
- Locations
- 🇺🇸
VA Boston Health Care System, Boston, Massachusetts, United States
D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD
- Conditions
- Interventions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Emory University
- Target Recruit Count
- 156
- Registration Number
- NCT00356278
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain
- Conditions
- Interventions
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 7
- Registration Number
- NCT00301080
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Wisconsin School of Medicine, Madison, Wisconsin, United States
D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- University of Florida
- Registration Number
- NCT00257361
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 240
- Registration Number
- NCT00222235
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States
🇮🇱Ezrath Nashim Association, Sarah Herzog Memorial Hospital, Jerusalem, Israel
🇺🇸UCLA/VA Greater Los Angeles Health Care System, Los Angeles, California, United States
Safety and Effectiveness of D-Cycloserine in Children With Autism
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 80
- Registration Number
- NCT00198120
- Locations
- 🇺🇸
Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States
Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 81
- Registration Number
- NCT00198107
- Locations
- 🇺🇸
Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.